AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca's (AZN) AZD7442 is a combination of two coronavirus-neutralizing monoclonal antibodies, AZD8895 and AZD1061.

AstraZeneca Begins Coronavirus Antibody Combo Phase I Study

Novavax

Pfizer

COVID-19 vaccine makers are lobbying the European Union for protection against lawsuits should problems arise with new therapies, the Financial Times reported Tuesday.

AstraZeneca, Novavax, Pfizer, Others Lobby EU For Legal Protection Against COVID-19 Vaccine Liabilities: FT

The U.K.-based drugmaker is hedges its bets with AZD7442.

AstraZeneca Starts Clinical Trial Testing Its COVID-19 Treatment Antibody Cocktail

Shares of AstraZeneca PLC (LON: AZN) gained over 1% on reports that the U.S. government considers fast-tracking the approval for Astrazeneca’s coronavirus vaccine in the States before the forthcoming presidential elections, according to a report by the Financial Times.

AstraZeneca stock price gains as Trump considers fast-tracking their COVID-19 vaccine

AstraZeneca noted an "important milestone" in starting trials for its coronavirus treatment, a day after news of possible quick approval of its coronavirus vaccine sent AZN stock higher.
The post AstraZeneca Coronavirus Treatment Testing Begins; 'Important Milestone' appeared first on Investor's Business Daily.

AstraZeneca Coronavirus Treatment Testing Begins; 'Important Milestone'

AstraZeneca's (AZN)/Oxford's AZD1222 is in phase II/III study in the UK, Brazil and South Africa with a late-stage study due to start soon in the United States with 30,000 participants.

AstraZeneca Coronavirus Vaccine May Get FDA's Emergency Tag

VANCOUVER, BC, Aug. 25, 2020 /PRNewswire/ -- USA News Group – In the fight against some of the most challenging forms of cancer, AstraZeneca PLC (NYSE:AZN) recently placed a giant $6 billion bet on an antibody-drug conjugate (ADC) called DS-1062 from Japanese developers Daiichi Sankyo.

Billions Pouring Into Drugs That Could Treat Cancer Patients with High TROP2 Expressions

Volunteers are receiving doses of drug, which has potential both as a vaccine and a treatment

Covid-19: AstraZeneca starts antibody drug trial in UK

The British drugmaker's COVID-19 vaccine candidate is already among the most advanced.

AstraZeneca starts trial of COVID-19 antibody treatment

One report suggests that the U.K.-based company might win the coronavirus vaccine race in the U.S.

AstraZeneca Might Receive Emergency Use Authorization for Its Coronavirus Vaccine

Gilead Sciences

Johnson & Johnson

Convalescent plasma contains antibodies that can fight off the disease faster and prevents COVID-19 patients from getting severely ill.

FDA Grants Emergency Use to Plasma Therapy to Treat Coronavirus

A report that the Trump administration could grant emergency use authorization to AstraZeneca's coronavirus vaccine candidate as early as October sent AZN stock rising near a buy point.
The post AstraZeneca Stock Up On Report FDA Could Soon OK Its Coronavirus Vaccine appeared first on Investor's Business Daily.

AstraZeneca Stock Up On Report FDA Could Soon OK Its Coronavirus Vaccine

The Trump administration is weighing a fast-tracked process that would allow AstraZeneca’s coronavirus vaccine to be used in the US before November’s presidential election, a new report says. One plan under consideration would see the Food and Drug Administration issue an “emergency use authorization” for the British drugmaker’s vaccine candidate in October, the Financial Times.

Trump reportedly considers fast-tracking AstraZeneca vaccine before election

AstraZeneca plc’s (NYSE: AZN) COVID-19 vaccine may be fast-tracked for approval in the United States, ahead of the impending presidential elections, the Financial Times reported Sunday.

AstraZeneca's Coronavirus Vaccine Could Get FDA Approval For Emergency Use By October: FT

US President Donald Trump is considering fast-tracking approval of a possible coronavirus vaccine so it can be used before the election, according to a report.

Trump wants to fast-track Oxford's potential coronavirus vaccine in time for election - report

The availability of a vaccine before the U.S. presidential election could allow President Donald Trump to justify his administration's handling of the coronavirus pandemic, which has faced widespread criticism.

Trump reportedly considers fast tracking AstraZeneca vaccine before election

Moderna

Coronavirus vaccine companies are attacking the virus and have late-stage trials underway. But the Covid vaccine timeline may not be what you think.

Coronavirus Vaccine Companies Target Best-Case Timeline — But What's The Worst Case?

BioNTech SE

Merck

What’s the best way for investors to gain diversified exposure to today's leading vaccine research? Here he recommends a 5-stock portfolio to boost your chances to benefit from potential progress made toward a successful Covid vaccine.

This 5-Stock Portfolio Is A Safe Bet On A Future COVID-19 Vaccine

CureVac B.V

Inovio Pharmaceuticals

Hope for a successful vaccine by the winter is fueling trials at a record pace.

COVID-19: The Real Results Are A Long Way Away

The FDA grants priority review to AstraZeneca's (AZN) sBLA seeking approval of Imfinzi for a four-week fixed-dose regimen for its approved indications in bladder cancer and non-small cell lung cancer.

AstraZeneca's Imfinzi Gets Priority Tag for 4-Week Dosing

A Relative Strength Rating upgrade for AstraZeneca shows improving technical performance. Will it continue?

Stocks Generating Improved Relative Strength: AstraZeneca

AstraZeneca (AZN) closes a deal with the European Commission for supplying at least 400 million doses of its COVID-19 vaccine, AZD1222, if approved.

AstraZeneca (AZN) to Supply Coronavirus Vaccine in Europe

Clorox

They're not the safest long-term investments to be holding in your portfolio.

Here's Why Buying Coronavirus Stocks Can Be Risky

Regeneron Pharmaceuticals

Both companies are leaders in the fight against COVID-19. But one appears to have a clear advantage.

Better Coronavirus Stock: AstraZeneca vs. Regeneron

GlaxoSmithKline

Eli Lilly

Novartis

AstraZenca, GlaxoSmithKline, Novartis and Eli Lilly are using artificial intelligence systems to help in drug development, decision-making, and more.

News for AstraZeneca Stock (AZN)